Covered recipient · General Payments record
STEVEN Y LIU
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$5,396.71
126 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,171.73 | 123 |
| Consulting Fee | $2,050.00 | 1 |
| Education | $174.98 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEVEN Y LIU
NPI 1164462834 · CMS profile ID 279230
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ANCHORAGE, AK
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
126 matching records · $5,396.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 126.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $27.56 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197086037 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.22 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666650 | CMS |
| GENZYME CORPORATION | $25.52 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233249798 | CMS |
| ABBVIE INC. | $24.01 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202314932 | CMS |
| ABBVIE INC. | $2.46 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202314934 | CMS |
| Incyte Corporation | $19.34 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226157329 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.53 | 07/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212976623 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.84 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206805617 | CMS |
| Lilly USA, LLC | $25.40 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186911142 | CMS |
| Rigel Pharmaceuticals, Inc. | $25.93 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247375410 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.30 | 07/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666619 | CMS |
| ABBVIE INC. | $32.59 | 07/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202314930 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.99 | 06/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206423345 | CMS |
| Caris MPI, Inc. | $16.67 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234282560 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6.96 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666614 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $24.73 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246116798 | CMS |
| Incyte Corporation | $23.95 | 06/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226167110 | CMS |
| Novartis Pharmaceuticals Corporation | $24.48 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755877 | CMS |
| Daiichi Sankyo Inc. | $99.99 | 06/16/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197087837 | CMS |
| Apellis Pharmaceuticals, Inc. | $25.99 | 06/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253207032 | CMS |
| Celgene Corporation | $29.92 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666560 | CMS |
| Gilead Sciences, Inc. | $18.12 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234547727 | CMS |
| Genentech USA, Inc. | $23.63 | 06/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211595214 | CMS |
| BeOne Medicines USA, Inc. | $13.32 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202902254 | CMS |
| GlaxoSmithKline, LLC. | $28.10 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191296090 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.75 | 05/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206153257 | CMS |
| Novartis Pharmaceuticals Corporation | $24.14 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755865 | CMS |
| SpringWorks Therapeutics, Inc. | $21.49 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232164537 | CMS |
| Caris MPI, Inc. | $25.65 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234282558 | CMS |
| AstraZeneca Pharmaceuticals LP | $55.09 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206310702 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.79 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207012394 | CMS |
| ARRAY BIOPHARMA INC | $14.37 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231311808 | CMS |
| Rigel Pharmaceuticals, Inc. | $32.97 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247373258 | CMS |
| Novartis Pharmaceuticals Corporation | $14.79 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755867 | CMS |
| Novartis Pharmaceuticals Corporation | $0.58 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755869 | CMS |
| E.R. Squibb & Sons, L.L.C. | $31.25 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666535 | CMS |
| Novartis Pharmaceuticals Corporation | $4.40 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755863 | CMS |
| BeOne Medicines USA, Inc. | $87.67 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202902252 | CMS |
| GENZYME CORPORATION | $31.63 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233249784 | CMS |
| EMD Serono, Inc. | $24.56 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236921479 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.59 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223919550 | CMS |
| Ipsen Biopharmaceuticals, Inc | $74.99 | 04/14/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208825143 | CMS |
| GlaxoSmithKline, LLC. | $24.36 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190906733 | CMS |
| Merck Sharp & Dohme LLC | $24.58 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238025958 | CMS |
| Novartis Pharmaceuticals Corporation | $21.76 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755859 | CMS |
| ABBVIE INC. | $32.60 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202314928 | CMS |
| BeOne Medicines USA, Inc. | $9.44 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202902256 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.43 | 03/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666499 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.43 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184666495 | CMS |
| Novartis Pharmaceuticals Corporation | $18.52 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200755871 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,802.65 | 2 |
| PY2025 | Principal investigator | $1,994,396.58 | 183 |
| PY2024 | Recipient | $8,496.64 | 5 |
| PY2024 | Principal investigator | $2,080,007.77 | 126 |
| PY2023 | Recipient | $1,356.60 | 1 |
| PY2023 | Principal investigator | $1,954,936.96 | 85 |
| PY2022 | Principal investigator | $713,493.97 | 29 |
| PY2021 | Principal investigator | $125,358.64 | 10 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
185 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,836.10 | 12/31/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology | A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 | No dispute reported | 06/30/2026 | 1232928936 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,126.00 | 12/23/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190327547 |
| Recipient | F. Hoffmann-La Roche AG | $1,218.32 | 12/12/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211539115 |
| Principal investigator 1 | BioNTech SE | $2,200.00 | 12/11/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | BNT327 | No dispute reported | 06/30/2026 | 1249018804 |
| Principal investigator 1 | BioNTech SE | $2,078.00 | 12/11/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | BNT327 | No dispute reported | 06/30/2026 | 1249018808 |
| Principal investigator 1 | BioNTech SE | $12,000.00 | 12/11/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | BNT327 | No dispute reported | 06/30/2026 | 1249018810 |
| Recipient | F. Hoffmann-La Roche AG | $584.33 | 12/08/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211539118 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $34,000.00 | 12/05/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | A Phase II Trial of BMS-986504 in Participants with Advanced and or Metastatic Non- Small Cell Lung Cancer with Homozygous MTAP Deletion After Progression on Prior Therapies | No dispute reported | 06/30/2026 | 1235999185 |
| Principal investigator 1 | Genentech, Inc. | $7,450.00 | 12/03/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL | No dispute reported | 06/30/2026 | 1211571017 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.60 | 12/01/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS1062-328 | No dispute reported | 06/30/2026 | 1223363184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $94.00 | 12/01/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS1062-328 | No dispute reported | 06/30/2026 | 1223363186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $263.20 | 12/01/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS1062-328 | No dispute reported | 06/30/2026 | 1223363188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.75 | 12/01/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS1062-328 | No dispute reported | 06/30/2026 | 1223363190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.80 | 12/01/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS1062-328 | No dispute reported | 06/30/2026 | 1223363192 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,000.99 | 11/24/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235927525 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,919.25 | 11/24/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235927530 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,073.25 | 11/24/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235927534 |
| Principal investigator 1 | BioNTech SE | $8,050.00 | 11/20/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | BNT327 | No dispute reported | 06/30/2026 | 1249018806 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,000.00 | 11/19/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185554655 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $46.64 | 11/19/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998623 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.00 | 11/19/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998625 |
| Principal investigator 1 | Genentech, Inc. | $72.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571044 |
| Principal investigator 1 | Genentech, Inc. | $17,910.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571048 |
| Principal investigator 1 | Genentech, Inc. | $3,828.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571052 |
| Principal investigator 1 | Genentech, Inc. | $340.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571056 |
| Principal investigator 1 | Genentech, Inc. | $189.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571060 |
| Principal investigator 1 | Genentech, Inc. | $248.00 | 11/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571064 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,220.10 | 11/06/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology, Llc | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1235999173 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,250.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) | No dispute reported | 06/30/2026 | 1185554649 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,400.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185554651 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570938 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570942 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570947 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570952 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570956 |
| Principal investigator 1 | Genentech, Inc. | $34,104.00 | 11/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570960 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/29/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571029 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/29/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571032 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 10/29/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571036 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571039 |
| Principal investigator 1 | Genentech, Inc. | $23,982.00 | 10/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1211571067 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,167.27 | 10/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190302929 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,425.85 | 10/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190302935 |
| Principal investigator 1 | Genentech, Inc. | $1,929.00 | 10/24/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570934 |
| Principal investigator 1 | Genentech, Inc. | $4,549.00 | 10/17/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211571013 |
| Principal investigator 1 | Genentech, Inc. | $16,078.00 | 10/16/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211570964 |
| Principal investigator 1 | Genentech, Inc. | $102,759.47 | 10/08/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211571009 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,225.00 | 10/06/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220815672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,254.00 | 10/02/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,500.00 | 10/02/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363341 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,400.00 | 10/02/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363343 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $3,800.00 | 10/02/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology, Llc | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236531292 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $100.00 | 10/01/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190302931 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,500.00 | 09/29/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology | A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 | No dispute reported | 06/30/2026 | 1232928892 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,329.00 | 09/23/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190327545 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $35,000.00 | 09/18/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | No dispute reported | 06/30/2026 | 1235999179 |
| Principal investigator 1 | Genentech, Inc. | $1,951.00 | 09/12/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570925 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $8,357.00 | 08/26/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190328571 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $33.94 | 08/26/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998619 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $23.32 | 08/26/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998621 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,305.13 | 08/26/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | No dispute reported | 06/30/2026 | 1235999181 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,919.25 | 08/06/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235927521 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $31,000.00 | 08/04/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination with Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1235999177 |
| Principal investigator 1 | Genentech, Inc. | $3,348.00 | 07/29/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211571005 |
| Principal investigator 1 | Genentech, Inc. | $1,929.00 | 07/09/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570930 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/18/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190337282 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,329.00 | 06/17/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190331049 |
| Principal investigator 1 | Celgene Corporation | $51,027.00 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology, Llc | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1222306671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363248 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363252 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363258 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363260 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363262 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363264 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363266 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363268 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363270 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363272 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363276 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363278 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363280 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363282 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363284 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363286 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363288 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363290 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363292 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363294 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363298 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363302 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363306 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363308 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363314 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363316 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363318 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363320 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363322 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363326 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363332 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363334 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 06/13/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | DS8201-793 | No dispute reported | 06/30/2026 | 1223363336 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,400.00 | 06/11/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185554653 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,140.00 | 06/04/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology, Llc | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | No dispute reported | 06/30/2026 | 1235999175 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,000.00 | 06/03/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190311771 |
| Principal investigator 1 | Genentech, Inc. | $5,526.00 | 06/02/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570972 |
| Principal investigator 1 | Genentech, Inc. | $14,678.00 | 05/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570967 |
| Principal investigator 1 | Genentech, Inc. | $54,555.00 | 05/14/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570994 |
| Principal investigator 1 | Genentech, Inc. | $5,567.00 | 05/09/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570918 |
| Principal investigator 1 | Genentech, Inc. | $378.00 | 05/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571025 |
| Principal investigator 1 | Genentech, Inc. | $26,209.00 | 04/25/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570997 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,160.54 | 04/23/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | A Phase II Trial of BMS-986504 in Participants with Advanced and or Metastatic Non- Small Cell Lung Cancer with Homozygous MTAP Deletion After Progression on Prior Therapies | No dispute reported | 06/30/2026 | 1235999183 |
| Principal investigator 1 | Genentech, Inc. | $8,870.00 | 04/22/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570984 |
| Principal investigator 1 | Genentech, Inc. | $44,957.00 | 04/22/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570989 |
| Principal investigator 1 | BeiGene, Ltd. | $3,329.00 | 04/17/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323954 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 04/14/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322246 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/10/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240500498 |
| Principal investigator 1 | Genentech, Inc. | $7,980.00 | 04/09/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570921 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,562.00 | 04/04/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220815670 |
| Principal investigator 1 | Genentech, Inc. | $9,786.00 | 04/01/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211571001 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 03/31/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323786 |
| Principal investigator 1 | Eli Lilly and Company | $264.06 | 03/10/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC. | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187875263 |
| Principal investigator 1 | BeiGene, Ltd. | $9,099.00 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323952 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $237.58 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998609 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $104.94 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998611 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998613 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $73.00 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998615 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.50 | 02/25/2025 | Non-covered Recipient Entity Alaska Oncology And Hematology | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220998617 |
| Principal investigator 1 | Genentech, Inc. | $1,951.00 | 02/12/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570910 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,000.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234181572 |
| Principal investigator 1 | Astellas Pharma Global Development | $13,550.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234181574 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,500.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234181576 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570894 |
| Principal investigator 1 | Genentech, Inc. | $2,750.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570901 |
| Principal investigator 1 | Genentech, Inc. | $8,277.00 | 02/05/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211571021 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $115,321.10 | 01/31/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190302937 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 01/29/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323816 |
| Principal investigator 1 | BeiGene, Ltd. | $12,961.00 | 01/28/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323948 |
| Principal investigator 1 | Genentech, Inc. | $15,057.00 | 01/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570977 |
| Principal investigator 1 | Genentech, Inc. | $686.00 | 01/28/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211570981 |
| Principal investigator 1 | BeiGene, Ltd. | $2,419.00 | 01/21/2025 | Non-covered Recipient Entity Alaska Oncology and Hematology, LLC | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323950 |
| Principal investigator 1 | Genentech, Inc. | $5,320.00 | 01/15/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570889 |
| Principal investigator 1 | Eli Lilly and Company | $84,657.32 | 01/08/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY, LLC. | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187876089 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 01/03/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570898 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 01/03/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570906 |
| Principal investigator 1 | Genentech, Inc. | $22,873.00 | 01/03/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211570914 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $618,261.95 | 01/01/2025 | Non-covered Recipient Entity ALASKA ONCOLOGY AND HEMATOLOGY | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190302933 |